Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711384 | 0.91 | EDNRA (0.31) | MEN1KMT2AATMEDNRA | |
| SCHEMBL7711412 | 0.83 | PARP1 (0.39) | PARP1SMYD3PDE3BPDE3AKDR | |
| SCHEMBL7711431 | 0.81 | PARP1 (0.37) | PARP1SMYD3PDE3BPDE3AKDR | |
| SCHEMBL7711106 | 0.81 | PDE3B (0.38) | PARP1SMYD3PDE3BPDE3AKDR | |
| SCHEMBL7705087 | 0.81 | EDNRA (0.31) | MEN1KMT2AATMEDNRA | |
| SCHEMBL7711394 | 0.80 | PARP1 (0.36) | PARP1SMYD3PDE3BPDE3AKDR | |
| SCHEMBL7708177 | 0.80 | MAPT (0.36) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL6998315 | 0.77 | SMYD3 (0.37) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL6998103 | 0.75 | PARP1 (0.46) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL7713347 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |